Ignite Creation Date:
2025-12-24 @ 7:13 PM
Ignite Modification Date:
2025-12-27 @ 8:50 AM
Study NCT ID:
NCT01768403
Status:
COMPLETED
Last Update Posted:
2013-01-15
First Post:
2013-01-14
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Centralised Pan-Algerian Survey on the Undertreatment of Hypercholesterolemia
Sponsor:
AstraZeneca
Organization:
Study Overview
Official Title:
Centralised Pan-Algerian Survey on the Undertreatment of Hypercholesterolemia
Status:
COMPLETED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CEPHEUS
Brief Summary:
Centralized Pan-Algerian Survey on the undertreatment of hypercholesterolemia. The purpose of this study is to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Third Joint European Task Force guidelines in the survey population.
Detailed Description:
Centralised Pan-Algerian Survey on the undertreatment of hypercholesterolemia.
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: